Stockscreener 앱 받기
1.725
0.29%
0.005
전일 마감가:
$1.72
열려 있는:
$1.73
하루 거래량:
342.22K
Relative Volume:
0.36
시가총액:
$73.50M
수익:
-
순이익/손실:
$-40.92M
주가수익비율:
-1.0048
EPS:
-1.7167
순현금흐름:
$-26.53M
1주 성능:
-1.43%
1개월 성능:
-1.43%
6개월 성능:
-35.63%
1년 성능:
-25.32%
1일 변동 폭
$1.70
$1.77
1주일 범위
$1.70
$1.8557
52주 변동 폭
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.725 | 76.27M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
541.87 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.93 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,024.42 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.38 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.11 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio, Inc. (ANVS) options chain - Yahoo Finance Singapore
Annovis Bio (ANVS) Edges Lower But Holds Above Key Support at $1.78Overvalued Signals - vinanet.vn
Annovis Bio Inc (ANVS) Stock News Today - TradingKey
Annovis Bio Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Annovis Bio (ANVS) Rallies 5% as Stock Approaches Key ResistanceVolume Breadth - dars.gov.et
Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake - Stock Titan
ANVS|Annovis Bio Inc|Price:1.665|Chg%:+0.005 - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (ANVS) Gains 1.8% as Shares Hold Above Key Support at $1.61Short Term Trading Ideas - dars.gov.et
Annovis Bio Inc (ANVS) Cash Flow - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Income Statement - TradingKey
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANVS|Annovis Bio Inc|Price:1.650|Chg%:-0.100 - TradingKey
ANVS|Annovis Bio Inc|Price:1.686|Chg%:+0.026 - TradingKey
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio, Inc. Revenue Breakdown – NYSE:ANVS - TradingView
ANVS stock holds support after recent clinical update - Ad-hoc-news.de
Annovis Bio (ANVS) Slips 0.57% to $1.74 as Stock Hovers Near Key SupportOvernight Profile - dars.gov.et
Annovis Bio (ANVS) Sits Near Support With Slight Decline: Key Levels in FocusStatistical Arbitrage - po-news-eg.net
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Annovis Bio Inc 주식 (ANVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
0.71%
1.65%
자본화:
|
볼륨(24시간):